[Perlmutter]: 1308, you're right. I mean, the -- our molecule looks pretty good. I mean, we've worked quite hard to select a CTLA-4-directed molecule and to try and establish what the appropriate dose and schedule would be for such a molecule. And we are interested in the question. Not sure why, but the combination looks a little promising. And so we think that there may be a possibility for it. We're sort of still stepping through it, haven't made explicit decisions, but it looks like there may be an opportunity there.